Theriva™ Biologics to Discuss the Trial Design for VIRAGE - a Phase 2b Clinical Study of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma - at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewsWire • Thursday
Theriva™ Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory RetinoblastomaGlobeNewsWire • Tuesday
Theriva™ Biologics to Present Preclinical Data Supporting the Potential Synergy of VCN-01 and First-Line Pancreatic Cancer Chemotherapy Regimens at the American Society for Cell and Gene Therapy 27th Annual MeetingGlobeNewsWire • Monday
Theriva™ Biologics Announces Presentation at the American Society for Cell and Gene Therapy 27th Annual MeetingGlobeNewsWire • 04/08/24
Theriva™ Biologics Reports Full-Year 2023 Operational Highlights and Financial ResultsGlobeNewsWire • 03/25/24
Theriva™ Biologics to Host Conference Call and Webcast to Discuss Full Year 2023 Operational Highlights and Financial ResultsGlobeNewsWire • 03/19/24
Theriva Biologics Announces Positive Recommendation from the Independent Data Monitoring Committee of VIRAGE, the Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal AdenocarcinomaGlobeNewsWire • 02/07/24
Theriva Biologics to Participate in the B. Riley Securities Annual Oncology ConferenceGlobeNewsWire • 01/16/24
Theriva™ Biologics Reports Third Quarter 2023 Operational Highlights and Financial ResultsGlobeNewsWire • 11/13/23
Theriva Biologics to Host Conference Call and Webcast to Discuss Third Quarter 2023 Operational Highlights and Financial ResultsGlobeNewsWire • 11/06/23
Theriva™ Biologics and Sant Joan de Déu-Barcelona Children's Hospital Advance Strategic Collaboration to Explore the Combination of VCN-01 with Topoisomerase Inhibitors to Treat CancerGlobeNewsWire • 11/02/23
Theriva™ Biologics Presents Survival Outcomes Data from Phase 1 Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck at ESMO Congress 2023GlobeNewsWire • 10/23/23
Theriva™ Biologics Announces Presentation at ESMO Congress 2023 Featuring Survival Outcomes in Phase 1 Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and NeckGlobeNewsWire • 10/16/23
Theriva™ Biologics Reports Second Quarter 2023 Operational Highlights and Financial ResultsGlobeNewsWire • 08/08/23
Theriva™ Biologics Announces Key Progress in VIRAGE, an Ongoing, Multinational Phase 2b Trial of VCN-01 in Combination with Chemotherapy in Pancreatic Ductal AdenocarcinomaGlobeNewsWire • 08/02/23
Theriva Biologics to Host Conference Call and Webcast to Discuss Second Quarter 2023 Operational Highlights and Financial ResultsGlobeNewsWire • 08/01/23
Theriva Biologics jumps on US FDA approval for pancreatic cancer treatmentProactive Investors • 06/28/23
Theriva Biologics Announces Orphan Drug Designation Granted by the U.S. FDA for VCN-01 for the Treatment of Pancreatic CancerGlobeNewsWire • 06/27/23
